System biology

By Andrii Lozoniuk Volume 21 Issue 2 – Spring 2020 Gathering compound solubility data is a key step during drug discovery that helps ensure cost-effective screening, yet it is a long process and is often underestimated in terms of difficulty. Global sharing of such data can help pharmaceutical companies minimise unnecessary expenditures in terms of […]

Target discovery and drug development what comes after CRISPR? By Benedict CS Cross Volume 21 Issue 2 – Spring 2020 For an area of research as important and impactful as drug discovery, it is surprising how often efforts in this field are directed by short-term trends. We have seen an abundance of new tools and […]

Reprogramming the stem cell for a new generation of cures By Dr Alex Davenport, Dr Tonya Frolov and Dr Mark Kotter Volume 21 Issue 2 – Spring 2020 The development of new and effective treatments with the potential to cure, or at the very least ease patient suffering, has been the driving force in biomedical […]

Drug development 2.0 – The partnership model in practice By Dr Brian Sheehan and Marco Cerato Over the last decade there has been a fundamental shift in the way in which drugs are developed and brought to market. Some years ago, the industry started to see profits falling as research and development (R&D) costs continued […]

Harnessing the modified proteome for increased diagnostic power By Dr David Bramwell, Dr Steven Laval and Dr Jane McLeod Relevant biomarkers are vitally important in personalised medicine, guiding patient matching to specific therapies for earlier, easier and more effective disease identification and treatment. Here we trace the expectations of ’omicsbased healthcare interventions, from the increased […]

Unlocking the potential of Extracellular Vesicles: from single molecules to novel therapeutics By Dr Anna Caballe and Dr Katarzyna Ginda-Makela As part of normal homeostasis, cells release different types of small-sized membrane vesicles to traffic analytes across membranes, communicate with other cells and remove unwanted cell content. These vesicles can range in size from 30nm […]

By Dr Steve Arlington and John Wise As part of its mission to help members anticipate and prepare for changes in the pharmaceutical industry, The Pistoia Alliance has developed a research paper which sets out to consider what the life science, biopharma R&D and healthcare ecosystem might look like in 2030, in particular how the […]

Evolution of User Experience for life sciences By Jacek Ziemski, Simon Fortenbacher, James Hoeksma, Jan Taubert, Roger Attrill, Paula de Matos, Andre Richter and Julie Morrison Since 2017 we have seen the slow and steady adoption of User Experience (UX) within the life sciences. User Experience is an evidence-based design process that centres on the […]

Using Live-Cell Imaging Systems to Transform Perspectives in Drug Discovery By Helen Stewart-Miller and Dr Kate Tointon Live-cell imaging has transformed the study of cell behaviour and function. The technique allows researchers to monitor internal cell structures, interactions and processes in real-time, and over time. In drug discovery, understanding the dynamic processes of cells provides […]

Unlocking Clinical Trial Data to Uncover New Therapeutic Opportunities By David Wang, Masha Hoffey and Dr Simone Sharma This article discusses opportunities, challenges and best practices in leveraging infrastructure excellence and AI to unlock the value of early or inconclusive clinical trial data. The goal… driving stronger biomarker-based insights and decisions and helping to advance […]